预约演示
更新于：2025-05-31
Morphine Sulfate/Naltrexone Hydrochloride
盐酸纳曲酮/硫酸吗啡水合物
更新于：2025-05-31
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段临床3期 |
首次获批日期 美国 (2009-08-13), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C74H88Cl2N4O18S |
InChIKeyFFSBSYUGIGJQOU-INJDZLCSSA-N |
CAS号1131418-84-2 |
关联
13
项与 盐酸纳曲酮/硫酸吗啡水合物 相关的临床试验CTR20240009
在中至重度癌痛患者中评价硫酸吗啡盐酸纳曲酮缓释胶囊的有效性和安全性的多中心、随机、双盲双模拟、平行、阳性对照临床试验
CTR20233537
碾碎的硫酸吗啡盐酸纳曲酮缓释胶囊、完整的硫酸吗啡盐酸纳曲酮缓释胶囊和盐酸纳曲酮溶液在慢性非癌性疼痛患者中的单中心、随机、开放、单剂量、三周期药代动力学对比研究
CTR20232248
硫酸吗啡盐酸纳曲酮缓释胶囊与硫酸吗啡缓释片的药代动力学对比研究
100 项与 盐酸纳曲酮/硫酸吗啡水合物 相关的临床结果
登录后查看更多信息
100 项与 盐酸纳曲酮/硫酸吗啡水合物 相关的转化医学
登录后查看更多信息
100 项与 盐酸纳曲酮/硫酸吗啡水合物 相关的专利（医药）
登录后查看更多信息
29
项与 盐酸纳曲酮/硫酸吗啡水合物 相关的文献（医药）2019-04-03Postgraduate medicine4区 · 医学
Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients
4区 · 医学
Article
作者: Schnoll, Sidney H. ; Dart, Richard C. ; Polson, Michael ; Mardekian, Jack ; Cattaneo, Michael ; Roland, Carl L. ; Park, Peter W. ; Cicero, Theodore J. ; Mendoza, Mario ; Webster, Lynn R.
OBJECTIVE:
Opioids with abuse-deterrent properties may reduce widespread abuse, misuse, and diversion of these products. This study aimed to quantify misuse, abuse, dependence, and health resource use of extended-release morphine sulfate with sequestered naltrexone hydrochloride (ER-MSN; EMBEDA®), compared with non-abuse-deterrent extended-release morphine (ERM) products in Medicaid non-cancer patients.
METHODS:
Administrative medical and pharmacy claims data were analyzed for 10 Medicaid states from 1 January 2015, to 30 June 2016. Patients were included if they received a prescription for ER-MSN or any oral, non-abuse-deterrent ERM. Index date was the date of first prescription for an ER-MSN or ERM. Abuse/dependence, non-fatal overdose, emergency department (ED) visits, and ED/inpatient readmissions were determined for each participant. An overall measure of misuse and abuse was also calculated. To account for differences in follow-up, all counts are expressed per 100 patient-years.
RESULTS:
There were 4,857 patients who received ER-MSN and 10,357 who received an ERM. The average age in the two cohorts was approximately 45 years old. From pre-index to follow-up, the number of patients per 100 patient-years with a diagnosis code indicating abuse or dependence increased by 0.91 (95% confidence interval [CI]: 0.85, 0.97) in the ER-MSN cohort and 2.23 (95% CI: 2.14, 2.32) in the ERM cohort. The number of patients per 100 patient-years with an opioid-related non-fatal overdose increased by 0.05 (95% CI: 0.04, 0.06) in the ER-MSN cohort compared with 0.11 (95% CI: 0.09, 0.13) in the ERM cohort. The opioid abuse overall composite score increased by 1.36 (95% CI: 1.24, 1.48) in the post-index period in the ER-MSN cohort compared to 3.21 (95% CI: 3.10, 3.32) in the ERM cohort.
CONCLUSION:
Misuse, abuse, and dependence events were numerically lower in patients receiving ER-MSN compared with those receiving ERM products.
2018-02-01Clinical therapeutics4区 · 医学
Challenges Involved in the Development and Delivery of Abuse-deterrent Formulations of Opioid Analgesics
4区 · 医学
Article
作者: Cohen, Joshua P ; Roland, Carl ; Mendoza, Mario
PURPOSE:
This commentary examines the development, regulatory, and reimbursement challenges facing abuse-deterrent formulation (ADF) products.
METHODS:
In January 2017, the Tufts Center for the Study of Drug Development convened a roundtable to explore clinical development, regulatory, and reimbursement challenges with respect to ADFs of opioid analgesics. Roundtable participants, who included a range of pharmaceutical industry and other experts, discussed multiple challenges.
FINDINGS:
First, several key clinical development challenges were identified and discussed. These challenges pertain to prodrug development and development of deterrents against oral abuse. Second, experts suggested that more clarity is needed from regulatory authorities regarding standards for proving ADF labeling claims and for being rewarded with 3-year data exclusivity. Similarly, given the substantial burdens associated with the development of postapproval evidence generation, experts raised the need for a consistent regulatory policy related to postapproval evidence generation for all ADFs (branded and generic). Third, despite the public health benefits of certain ADF products, current coverage and access policies impede patient access. Payer justification for restrictive policies appears to be based more on budget impact considerations than cost-effectiveness. Fourth, there remains a need to further expand the evidence base regarding clinical and cost-effectiveness as well as abuse deterrence in a real-world setting for all ADF products.
IMPLICATIONS:
Clinical development challenges need to be overcome with respect to novel ADF technologies, such as prodrugs and deterrents against oral abuse. More clarity is needed from regulatory authorities on labeling claims and data exclusivity eligibility with respect to ADFs. Ensuring prescriber training and awareness of various options for treating pain, including ADF products, is an important step, as is educating payers about the public health benefits of ADFs in appropriate subpopulations of pain patients. In addition, physicians may need to incorporate appropriate risk stratification methods. Finally, it is important to establish a level playing field between coverage of ADF and non-ADF products so that non-ADF products are not given preferred formulary placement.
2016-03-03Current medical research and opinion4区 · 医学
Safety profile of extended-release morphine sulfate with sequestered naltrexone hydrochloride in older patients: pooled analysis of three clinical trials
4区 · 医学
Article
作者: Setnik, Beatrice ; Webster, Lynn R. ; Pixton, Glenn C.
OBJECTIVE:
Clinical trial safety data following chronic administration of extended-release opioids within an older population is limited. Embeda * is an extended-release formulation of morphine sulfate surrounding sequestered naltrexone hydrochloride (MSN) and is designed to deter opioid misuse and abuse. The present analysis compared pooled safety outcomes among patients aged ≥65 years and those aged <65 years from three phase 2/3 studies (ranging from 2 weeks to 12 months) in patients treated with MSN.
RESEARCH DESIGN AND METHODS:
Subgroup analysis of patients aged ≥65 years and <65 years was performed on pooled data for adverse events (AEs), potentially clinically significant laboratory values (hematology/chemistry), and signs/symptoms of opioid withdrawal using the Clinical Opiate Withdrawal Scale (COWS) (phase 3 trials only) for patients who received at least one dose (short-term studies, maximum dose was 160 mg/d or 320 mg/d depending on study; long-term study, no maximum dose) of study medication during titration and maintenance phases.
CLINICAL TRIAL REGISTRATION:
ClinicalTrials.gov: NCT00420992, NCT00415597.
RESULTS:
During titration, 173 (17.1%) of 1012 patients treated with MSN were aged ≥65 years, while during maintenance 76/564 (13.5%) patients were aged ≥65 years. Treatment-emergent AEs were similar in frequency and type between the two cohorts, with the most common being constipation, nausea, and somnolence; no consistent patterns relating to age and only one possibly treatment-related serious AE in patients ≥65 years was noted. No clinically significant differences in laboratory values or COWS scores (average maximum score ≤2.5) were observed between age groups.
CONCLUSIONS:
Safety outcomes following daily administration of MSN (2 weeks-12 months) were similar between patients aged ≥65 years and <65 years. Key limitations include the variable study designs and length of treatment (2 weeks-12 months), small sample size, and the inclusion of only those patients who were otherwise in relatively good health with restrictions on concomitant medications.
5
项与 盐酸纳曲酮/硫酸吗啡水合物 相关的新闻（医药）2024-12-11
·米内网
上市批准医药出海申请上市
2024-12-01
·信狐药迅
细胞疗法申请上市免疫疗法临床申请ASH会议
2024-12-01
·药筛
100 项与 盐酸纳曲酮/硫酸吗啡水合物 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 盐酸纳曲酮/硫酸吗啡水合物 | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 疼痛 | 美国 | 2009-08-13 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 癌症疼痛 | 临床3期 | 中国 | 2024-02-05 | |
| 慢性疼痛 | 临床3期 | 美国 | 2006-12-01 | |
| 膝关节炎 | 临床3期 | 美国 | 2006-12-01 | |
| 阿片滥用 | 临床1期 | 美国 | 2011-02-01 | |
| 镇痛 | 临床1期 | - | 2010-08-01 | |
| 麻醉相关疾病 | 临床1期 | - | 2010-08-01 | |
| 阿片相关性障碍 | 临床1期 | - | 2010-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 684 | naltrexone hydrochloride+morphine sulfate+EMBEDA | 鬱願餘餘鹹齋鹹遞選衊 = 醖觸膚鬱網選獵廠鑰衊 鹽膚選淵獵蓋衊構餘醖 (選憲齋築蓋淵願觸遞築, 壓繭鬱顧壓襯醖積衊窪 ~ 鬱範壓艱範獵蓋鑰襯鬱) 更多 | - | 2012-09-05 | ||
临床4期 | 14 | placebo+EMBEDA (EMBEDA Whole Capsules) | 網窪衊齋鏇構觸窪構願 = 淵衊窪鹹憲鏇網憲積構 艱遞鹹鹽壓齋夢願艱齋 (憲齋膚膚願鏇襯鹹構鑰, 糧襯願願憲窪築鏇積醖 ~ 築淵積窪選選築鹹鬱築) 更多 | - | 2012-03-28 | ||
placebo+EMBEDA (EMBEDA Crushed in Solution) | 網窪衊齋鏇構觸窪構願 = 淵積積襯窪網壓觸簾繭 艱遞鹹鹽壓齋夢願艱齋 (憲齋膚膚願鏇襯鹹構鑰, 廠廠蓋糧齋窪齋鬱鏇範 ~ 網積窪鏇憲齋壓鹽顧醖) 更多 | ||||||
临床3期 | 467 | 觸廠憲廠積艱獵網築鏇 = 鑰鏇繭鬱構獵窪鏇鏇網 憲蓋蓋鏇鑰壓顧齋構遞 (獵壓淵醖鹹鑰製壓餘糧, 製觸糧築獵憲範襯願廠 ~ 窪齋憲蓋壓簾獵壓積鏇) 更多 | - | 2009-10-29 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用